From Analysis:
Circuit-level neural dynamics in neurodegeneration
Analyze circuit-level changes in neurodegeneration using Allen Institute Neural Dynamics data. Focus on: (1) hippocampal circuit disruption, (2) cortical dynamics alterations, (3) sensory processing changes. Identify circuit-based therapeutic targets connecting genes, proteins, and brain regions to neurodegeneration phenotypes.
No AI visual card yet
Curated pathway diagram from expert analysis
graph TD
SST["SST gene
somatostatin interneurons"] --> PV["PV+ interneurons
parvalbumin positive"]
PV --> GAMMA_GEN["Gamma oscillation
generation 40Hz"]
GAMMA_GEN --> HIPP_SYNC["Hippocampal
gamma rhythm"]
GAMMA_GEN --> CORT_SYNC["Cortical
gamma rhythm"]
AMYLOID["Amyloid beta
accumulation"] --> GAMMA_RED["Reduced gamma power
40-70% decrease"]
TAU["Tau pathology
neurofibrillary tangles"] --> GAMMA_RED
GAMMA_RED --> DESYNC["Hippocampal-cortical
desynchronization"]
DESYNC --> MEM_IMP["Memory impairment
encoding and retrieval"]
GET["Gamma entrainment
therapy 40Hz"] --> GAMMA_REST["Gamma rhythm
restoration"]
GAMMA_REST --> SYNC_REC["Synchrony recovery
between regions"]
SYNC_REC --> MEM_IMPROVE["Memory function
improvement"]
HIPP_SYNC --> SYNC_NORM["Normal hippocampal-
cortical synchrony"]
CORT_SYNC --> SYNC_NORM
SYNC_NORM --> MEM_NORM["Normal memory
function"]
style SST fill:#ce93d8
style PV fill:#4fc3f7
style GAMMA_GEN fill:#4fc3f7
style HIPP_SYNC fill:#4fc3f7
style CORT_SYNC fill:#4fc3f7
style SYNC_NORM fill:#4fc3f7
style MEM_NORM fill:#4fc3f7
style AMYLOID fill:#ef5350
style TAU fill:#ef5350
style GAMMA_RED fill:#ef5350
style DESYNC fill:#ef5350
style MEM_IMP fill:#ef5350
style GET fill:#81c784
style GAMMA_REST fill:#81c784
style SYNC_REC fill:#ffd54f
style MEM_IMPROVE fill:#ffd54f
Median TPM across 13 brain regions for PVALB from GTEx v10.
BACKGROUND: Tremor is one of the most prevalent symptoms in Parkinson's Disease (PD). The progression and management of tremor in PD can be challenging, as response to dopaminergic agents might be relatively poor, particularly in patients with tremor-dominant PD compared to the akinetic/rigid subtype. In this review, we aim to highlight recent advances in the underlying pathogenesis and treatment modalities for tremor in PD. METHODS: A structured literature search through Embase was conducted using the terms "Parkinson's Disease" AND "tremor" OR "etiology" OR "management" OR "drug resistance" OR "therapy" OR "rehabilitation" OR "surgery." After initial screening, eligible articles were selected with a focus on published literature in the last 10 years. DISCUSSION: The underlying pathophysiology of tremor in PD remains complex and incompletely understood. Neurodegeneration of dopaminergic neurons in the retrorubral area, in addition to high-power neural oscillations in the cerebello-tha
Magnetoencephalography (MEG), a direct measure of neuronal activity, is an underexplored tool in the search for biomarkers of Alzheimer's disease (AD). In this study, we used MEG source estimates of auditory gating generators, nonlinear correlations with neuropsychological results, and multivariate analyses to examine the sensitivity and specificity of gating topology modulation to detect AD. Our results demonstrated the use of MEG localization of a medial prefrontal (mPFC) gating generator as a discrete (binary) detector of AD at the individual level and resulted in recategorizing the participant categories in: (1) controls with mPFC generator localized in response to both the standard and deviant tones; (2) a possible preclinical stage of AD participants (a lower functioning group of controls) in which mPFC activation was localized to the deviant tone only; and (3) symptomatic AD in which mPFC activation was not localized to either the deviant or standard tones. This approach showed
Despite expanding knowledge regarding the role of astroglia in regulating neuronal function, little is known about regional or functional subgroups of brain astroglia and how they may interact with neurons. We use an astroglia-specific promoter fragment in transgenic mice to identify an anatomically defined subset of adult gray matter astroglia. Using transcriptomic and histological analyses, we generate a combinatorial profile for the in vivo identification and characterization of this astroglia subpopulation. These astroglia are enriched in mouse cortical layer V; express distinct molecular markers, including Norrin and leucine-rich repeat-containing G-protein-coupled receptor 6 (LGR6), with corresponding layer-specific neuronal ligands; are found in the human cortex; and modulate neuronal activity. Astrocytic Norrin appears to regulate dendrites and spines; its loss, as occurring in Norrie disease, contributes to cortical dendritic spine loss. These studies provide evidence that hum
Mechanical anisotropy is an essential property for many biomolecules to assume their structures, functions and applications, however, the mechanisms for their direction-dependent mechanical responses remain elusive. Herein, by using a single-molecule nanopore sensing technique, we explore the mechanisms of directional mechanical stability of the xrRNA1 RNA from ZIKA virus (ZIKV), which forms a complex ring-like architecture. We reveal extreme mechanical anisotropy in ZIKV xrRNA1 which highly depends on Mg2+ and the key tertiary interactions. The absence of Mg2+ and disruption of the key tertiary interactions strongly affect the structural integrity and attenuate mechanical anisotropy. The significance of ring structures in RNA mechanical anisotropy is further supported by steered molecular dynamics simulations in combination with force distribution analysis. We anticipate the ring structures can be used as key elements to build RNA-based nanostructures with controllable mechanical anis
BACKGROUND: Gamification refers to the use of game elements in nongame contexts. The use of gamification to change behaviors and promote physical activity (PA) is a promising avenue for tackling the global physical inactivity pandemic and the current prevalence of chronic diseases. However, there is no evidence of the effectiveness of gamified interventions with the existence of mixed results in the literature. OBJECTIVE: The aim of this systematic review and meta-analysis is to evaluate the effectiveness of gamified interventions and their health care potential by testing the generalizability and sustainability of their influence on PA and sedentary behavior. METHODS: A total of 5 electronic databases (PubMed, Embase, Scopus, Web of Science, and the Cochrane Central Register of Controlled Trials) were searched for randomized controlled trials published in English from 2010 to 2020. Eligibility criteria were based on the components of the participants, interventions, comparators, and o
BACKGROUND: Nettle is a medicinal plant rich in bioactive molecules. The composition of nettle leaves and stems has been extensively studied, whereas the root has been insufficiently investigated. Therefore, the present study aimed to optimize the parameters of advanced extraction technique, pressurized liquid extraction (PLE), for the lipid fraction of nettle root rich in triterpenoid derivatives and to compare the efficiency of isolation under optimal conditions with conventional Soxhlet extraction (SE). RESULTS: The PLE yields ranged from 0.39-1.63%, whereas the total content of triterpenoid derivatives ranged from 43.50-78.26 mg 100 g-1 , with nine sterols and three pentacyclic triterpenoids identified and quantified within a total range of 42.81-76.57 mg 100 g-1 and 0.69-1.68 mg 100 g-1 dried root, respectively. The most abundant sterol and pentacyclic triterpenoid were β-sitosterol and β-amyrin acetate, with mean values of 50.21 mg 100 g-1 and 0.56 mg 100 g-1 dried root. CONCLUSI
Despite the promising antitumor activity of SHP2 inhibitors in RAS-dependent tumours, overall responses have been limited by their narrow therapeutic window. Like with all MAPK pathway inhibitors, this is likely the result of compensatory pathway activation mechanisms. However, the underlying mechanisms of resistance to SHP2 inhibition remain unknown. The E3 ligase SMURF2 limits TGFβ activity by ubiquitinating and targeting the TGFβ receptor for proteosome degradation. Using a functional RNAi screen targeting all known phosphatases, we identify that the tyrosine phosphatase SHP2 is a critical regulator of TGFβ activity. Specifically, SHP2 dephosphorylates two key residues on SMURF2, resulting in activation of the enzyme. Conversely, SHP2 depletion maintains SMURF2 in an inactive state, resulting in the maintenance of TGFβ activity. Furthermore, we demonstrate that depleting SHP2 has significant implications on TGFβ-mediated migration, senescence, and cell survival. These effects can be
Alzheimer's and Parkinson's diseases are the most prevalent neurodegenerative disorders in aging. Hyposmia has been described as an early symptom that can precede cognitive and motor deficits by decades. Certain regions within the olfactory system, such as the anterior olfactory nucleus, display the neuropathological markers tau and amyloid-β or α-synuclein from the earliest stages of disease progression in a preferential manner. Specific neuronal subpopulations, namely those expressing somatostatin (SST), are preferentially affected throughout the olfactory and limbic systems. SST is a neuropeptide present in a subpopulation of GABAergic interneurons throughout the brain and its main function is to inhibit principal neurons and/or other interneurons. It has been reported that SST expression is reduced by 50% in Alzheimer's disease and that it is related to the formation of Aβ oligomers. The mechanisms underlying the preferential vulnerability of SST-expressing neurons in Alzheimer's d
Among the central features of Alzheimer's disease (AD) progression are altered levels of the neuropeptide somatostatin (SST), and the colocalisation of SST-positive interneurons (SST-INs) with amyloid-β plaques, leading to cell death. In this theoretical review, I propose a molecular model for the pathogenesis of AD based on SST-IN hypofunction and hyperactivity. Namely, hypofunctional and hyperactive SST-INs struggle to control hyperactivity in medial regions in early stages, leading to axonal Aβ production through excessive presynaptic GABAB inhibition, GABAB1a/APP complex downregulation and internalisation. Concomitantly, excessive SST-14 release accumulates near SST-INs in the form of amyloids, which bind to Aβ to form toxic mixed oligomers. This leads to differential SST-IN death through excitotoxicity, further disinhibition, SST deficits, and increased Aβ release, fibrillation and plaque formation. Aβ plaques, hyperactive networks and SST-IN distributions thereby tightly overlap
Amyloids play critical roles in human diseases but have increasingly been recognized to also exist naturally. Shared physicochemical characteristics of amyloids and of their smaller oligomeric building blocks offer the prospect of molecular interactions and crosstalk amongst these assemblies, including the propensity to mutually influence aggregation. A case in point might be the recent discovery of an interaction between the amyloid β peptide (Aβ) and somatostatin (SST). Whereas Aβ is best known for its role in Alzheimer disease (AD) as the main constituent of amyloid plaques, SST is intermittently stored in amyloid-form in dense core granules before its regulated release into the synaptic cleft. This review was written to introduce to readers a large body of literature that surrounds these two peptides. After introducing general concepts and recent progress related to our understanding of amyloids and their aggregation, the review focuses separately on the biogenesis and interactions
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited treatment options. Currently approved agents, such as acetylcholinesterase inhibitors and NMDA receptor antagonists, provide only modest symptomatic benefit without modifying disease progression. Increasing evidence highlights the somatostatin (SST) system and its analogues (SSAs) as potential multitarget therapies. Somatostatin receptors (SSTR1-5) are widely expressed in cognition-related brain regions and participate in amyloid-β metabolism, tau phosphorylation, neuroinflammation, and synaptic plasticity. Preclinical studies suggest that SSAs enhance amyloid clearance via neprilysin activation, attenuate tau pathology through PI3K/Akt signaling, regulate APOE4 expression, and modulate microglial function, thereby protecting synaptic integrity. Compared with current monotherapies, SSAs may provide broader therapeutic benefits, particularly if applied in prodromal or early stages of AD. Advances in delive
Impairments in working memory and cognitive flexibility are early and consistent features of both Alzheimer's disease (AD) and stress. These functions depend critically on prefrontal cortical (PFC) circuits, which are particularly vulnerable to neuromodulatory and pathological insults. Recent studies suggest that stress and AD do not simply act globally, but instead converge on specific molecular and cellular targets within distinct neural populations. Notably, both chronic stress and Alzheimer's disease models exhibit dysregulation of synaptic signaling via NR2B-containing NMDA receptors and aberrant GSK-3β activation. These changes often emerge in a cell-type-specific manner, affecting excitatory pyramidal neurons and vulnerable interneuron subtypes such as SST+, PV+, and VIP + cells. The resulting imbalance in excitation and inhibition disrupts the integrity of prefrontal circuits, impairing adaptive behavior. This review synthesizes evidence across molecular, cellular, and circuit
Hippocampal interneurons (INs) play a fundamental role in regulating neural oscillations, modulating excitatory circuits, and shaping spatial representation. While historically overshadowed by excitatory pyramidal cells in spatial coding research, recent advances have demonstrated that inhibitory INs not only coordinate network dynamics but also contribute directly to spatial information processing. This review aims to provide a novel integrative perspective on how distinct IN subtypes participate in spatial coding and how their dysfunction contributes to cognitive deficits in neurological disorders such as epilepsy, Alzheimer's disease (AD), traumatic brain injury (TBI), and cerebral hypoxia-ischemia. We synthesize recent findings demonstrating that different IN classes-including parvalbumin (PV)-, somatostatin (SST)-, cholecystokinin (CCK)-, and calretinin (CR)-expressing neurons-exhibit spatially selective activity, challenging traditional views of spatial representation, and influe
The hypothesis correctly identifies parvalbumin-positive (PV+) fast-spiking interneurons as critical for gamma oscillation generation in hippocampal CA1. This is well-supported by extensive literature:
Critical flaw: The hypothesis claims tFUS directly activates Nav1.1, Cav2.1, Cav1.3, Piezo1, and TREK-1 to trigger a specific molecular cascade. This assumes:
Target Identification:
|
| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Mechanistic Plausibility | 0.82 | The PV+ interneuron → gamma oscillation link is robustly established (Cardin et al., PMID:19339603; Buzsáki & Wang, 2012). However, the hypothesis overstates mechanistic precision by claiming direct activation of specific voltage-gated channels (Nav1.1, Cav2.1, Cav1.3) via tFUS. Evidence for mechanosensitive activation of these channels remains indirect. |
| **Evidence Str
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for PVALB.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
PVALB["PVALB"] -->|generates| gamma_oscillation["gamma_oscillation"]
PVALB_1["PVALB"] -->|regulates| PV__interneurons["PV+ interneurons"]
PVALB_2["PVALB"] -->|therapeutic target| Alzheimer_s_disease["Alzheimer's disease"]
PVALB_3["PVALB"] -->|participates in| Prefrontal_inhibitory_cir["Prefrontal inhibitory circuits"]
PVALB_4["PVALB"] -->|associated with| Alzheimer_s_disease_5["Alzheimer's disease"]
PVALB_6["PVALB"] -->|studied in| neuroscience["neuroscience"]
PVALB_7["PVALB"] -->|expressed in| PV_interneurons["PV_interneurons"]
PVALB_SST["PVALB/SST"] -->|associated with| neuroscience_8["neuroscience"]
PVALB_9["PVALB"] -->|implicated in| neurodegeneration["neurodegeneration"]
BDNF["BDNF"] -->|co associated with| PVALB_10["PVALB"]
PVALB_11["PVALB"] -->|associated with| alzheimer_s_disease["alzheimer_s_disease"]
PVALB_12["PVALB"] -->|involved in| prefrontal_inhibitory_cir["prefrontal_inhibitory_circuits"]
CAMK2A["CAMK2A"] -->|co associated with| PVALB_SST_13["PVALB/SST"]
CHAT["CHAT"] -->|co associated with| PVALB_SST_14["PVALB/SST"]
GRIN2B["GRIN2B"] -->|co associated with| PVALB_SST_15["PVALB/SST"]
style PVALB fill:#ce93d8,stroke:#333,color:#000
style gamma_oscillation fill:#81c784,stroke:#333,color:#000
style PVALB_1 fill:#ce93d8,stroke:#333,color:#000
style PV__interneurons fill:#4fc3f7,stroke:#333,color:#000
style PVALB_2 fill:#ce93d8,stroke:#333,color:#000
style Alzheimer_s_disease fill:#ef5350,stroke:#333,color:#000
style PVALB_3 fill:#ce93d8,stroke:#333,color:#000
style Prefrontal_inhibitory_cir fill:#81c784,stroke:#333,color:#000
style PVALB_4 fill:#ce93d8,stroke:#333,color:#000
style Alzheimer_s_disease_5 fill:#ef5350,stroke:#333,color:#000
style PVALB_6 fill:#ce93d8,stroke:#333,color:#000
style neuroscience fill:#4fc3f7,stroke:#333,color:#000
style PVALB_7 fill:#ce93d8,stroke:#333,color:#000
style PV_interneurons fill:#4fc3f7,stroke:#333,color:#000
style PVALB_SST fill:#ce93d8,stroke:#333,color:#000
style neuroscience_8 fill:#ef5350,stroke:#333,color:#000
style PVALB_9 fill:#ce93d8,stroke:#333,color:#000
style neurodegeneration fill:#ef5350,stroke:#333,color:#000
style BDNF fill:#ce93d8,stroke:#333,color:#000
style PVALB_10 fill:#ce93d8,stroke:#333,color:#000
style PVALB_11 fill:#ce93d8,stroke:#333,color:#000
style alzheimer_s_disease fill:#ef5350,stroke:#333,color:#000
style PVALB_12 fill:#ce93d8,stroke:#333,color:#000
style prefrontal_inhibitory_cir fill:#81c784,stroke:#333,color:#000
style CAMK2A fill:#ce93d8,stroke:#333,color:#000
style PVALB_SST_13 fill:#ce93d8,stroke:#333,color:#000
style CHAT fill:#ce93d8,stroke:#333,color:#000
style PVALB_SST_14 fill:#ce93d8,stroke:#333,color:#000
style GRIN2B fill:#ce93d8,stroke:#333,color:#000
style PVALB_SST_15 fill:#ce93d8,stroke:#333,color:#000
neuroscience | 2026-04-03 | completed
No comments yet. Be the first to comment!